<DOC>
	<DOCNO>NCT00360087</DOCNO>
	<brief_summary>This study ass safety efficacy bosentan therapy ( study know ASSET ) patient high blood pressure lung associate sickle cell disease . That form hypertension place people risk complication , include shortness breath , pain , pneumonia , death . Previous study show bosentan helpful reduce pulmonary hypertension . Patients age 16 older complete 16-week treatment ASSET 1 ASSET 2 study pregnant breastfeeding may eligible study . The research conduct 25 hospital United States Europe . Up 30 participant enrol . The screen visit involve physical examination , blood sample 3 teaspoon laboratory test , pregnancy test . Patients ' doctor give bosentan tablet ( 62.5 mg ) , take one morning one evening . After 1 month , patient tell whether dose increase 125 mg tablet take twice day . Two week increase dose , blood test do analyze drug 's effect liver . After start treatment , patient return visit every 6 month , 6-minute walk test measure exercise capacity evaluate shortness breath . There follow-up patient end study 28 day last dose bosentan take , collect information side effect . Some patient bosentan change liver function red blood cell count . Side effect commonly report headache , flush appearance , inflammation throat nasal passage , gastrointestinal symptom . If patient sudden worsen breathe first week take bosentan , immediately tell doctor , may necessary change treatment .</brief_summary>
	<brief_title>A Study Patients Having Pulmonary Hypertension Associated With Sickle Cell Disease Completing ASSET Study</brief_title>
	<detailed_description>The object study ass long-term safety , tolerability efficacy bosentan patient pulmonary hypertension ( PH ) associate sickle cell disease ( SCD ) . The study population include male female patient sickle cell disease ( SS , S-beta-Thalassemia ) previously complete 16-week treatment period double-blind study bosentan ( ASSET 1 ASSET 2 ) . Patients meet inclusion criterion none exclusion criterion start 62.5 mg bid 4 week start maintenance dose 125 mg bid ( stay 62.5 mg weight less 40kg/90lbs ) . Patients divide two group . Group A consist patient begin study within 4 week complete ASSET 1 ASSET2 . Group B consist patient begin study longer 4 week complete ASSET I ASSET 2 . Patients remain drug FDA approve drug use patient pulmonary hypertension sponsor decide stop study .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Anemia , Sickle Cell</mesh_term>
	<mesh_term>Bosentan</mesh_term>
	<criteria>INCLUSION CRITERIA Completion 16week treatment period doubleblind ASSET study Women childbearing potential must negative result serum pregnancy test use reliable method contraception study treatment 3 month study treatment termination . Reliable method contraception : 1 . Barrier type device ( e.g. , female condom , diaphragm , contraceptive sponge ) combination spermicide . 2 . Intrauterine device . 3 . Oral , injectable , transdermal implantable contraceptive combination barrier method . Hormonebased contraceptive alone , regardless route administration , consider reliable method contraception . Abstention , rhythm method , contraception partner alone acceptable method contraception . Women childbearing potential defined prepubescent , postmenopausal ( i.e. , amenorrhea least 1 year ) , surgically naturally sterile . Signed write informed consent obtain patient patient 's parent/ legal representative prior initiation studyrelated procedure . EXCLUSION CRITERIA All patient ( Groups A B ) : 1 . Any major protocol violation precede doubleblind ASSET study* . 2 . Hemoglobin concentration le 6.0 g/dL . 3 . Pregnancy breastfeed . * Protocol violation review monitor site visit discuss study staff ongoing basis patient 's completion doubleblind study . Group B : 4 . Acute liver disease . 5 . Newly diagnose cirrhosis portal hypertension . 6 . ALT great equal 3 time ULN and/or albumin great 20 % LLN . 7 . Newly diagnose psychotic , addictive disorder limit ability provide inform consent comply study requirement .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>Treatment Study</keyword>
	<keyword>Sickle Cell Anemia</keyword>
	<keyword>6-Minute Walk</keyword>
	<keyword>Right Heart Catheterization</keyword>
	<keyword>Tracleer</keyword>
	<keyword>Sickle Cell</keyword>
	<keyword>SCD</keyword>
</DOC>